MedTrace Logo

Assessment of Metformin as Adjuvant Therapy in Patients With Ulcerative Colitis

NCT04750135 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-02-11

No results posted yet for this study

Summary

Brief Summary:

This is a randomized, controlled study evaluating metformin tablets administered daily for 8 weeks. The purpose of the study is to evaluate the efficacy and safety of metformin in the treatment of mild to moderately active ulcerative colitis. Disease activity will be measured using Mayo score for ulcerative colitis activity. Calculation of the score requires patients to undergo colonoscopy at the start of the study and at week 8.

Conditions

Interventions

DRUG

metformin 500 mg TID Oral Tablet

biguanides derivatives

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • National Hepatology & Tropical Medicine Research Institute

    lead OTHER_GOV

Principal Investigators

  • Noha Mansour, PhD · Mansoura University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-07
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04750135 on ClinicalTrials.gov